Analysis of Biological Progression and Regression of HELLP Syndrome in Time

March 29, 2026 updated by: Meryem Essafti, CHU Mohammed VI Marrakech

Biological Evolution of HELLP Syndrome

Prospective observational study about progression and regression of biological parameters of HELLP syndrome

Study Overview

Status

Completed

Conditions

Detailed Description

Data collection included a comprehensive review of pathological histories, identification of complications based on clinical presentation, daily monitoring of biological parameters, documentation of transfusion events, recording of corticosteroid administration according to gestational age, and detailed reporting of extraction and analgesia techniques.

Study Type

Observational

Enrollment (Actual)

72

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Morocco
    • Marrakech - Safi
      • Marrakesh, Marrakech - Safi, Morocco, 40000
        • CHU Mohammed VI of Marrakech

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Pregnant patients admitted to the maternal ICU from the Obstetrics Emergency department of marrakesh

Description

Inclusion Criteria:

  • Pregnant women who are admitted to the maternal ICU for a biological HELLP syndrome

Exclusion Criteria:

  • Patients whose biological presentation was attributable to other conditions, such as microangiopathies or leukemia.
  • Patients who benefited from plasma exchange therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Platelets count
Time Frame: Up to 10 days
Platelets count will be monitored daily before and after delivery
Up to 10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Concentration of Lactate dehydrogenase
Time Frame: Up to 10 days
Monitored daily before and after delivery
Up to 10 days
Concentration of Liver enzymes
Time Frame: Up to 10 days
daily monitoring of alkaline phosphatase, alanine transaminase before and after delivery
Up to 10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

CHU Mohammed VI Marrakech

Investigators

  • Study Director: Meryem Essafti, Assistant Professor, CHU Mohammed VI Marrakech

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2023

Primary Completion (Actual)

July 31, 2025

Study Completion (Actual)

August 31, 2025

Study Registration Dates

First Submitted

December 15, 2024

First Submitted That Met QC Criteria

December 28, 2024

First Posted (Actual)

January 6, 2025

Study Record Updates

Last Update Posted (Actual)

March 31, 2026

Last Update Submitted That Met QC Criteria

March 29, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 67/2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All data collected throughout the trial will be shared

IPD Sharing Time Frame

Beginning 3 months and ending 1 year after the publication of results

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preeclampsia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe